PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program

MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics’ products and... Read more

PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing

SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS). This collaboration aims to accelerate cancer research by leveraging PacBio’s advanced sequencing technologies, including the innovative Onso short-read sequencing platform,... Read more

Singapore’s National Precision Medicine (NPM) programme will partner with PacBio to propel HiFi Sequencing in Southeast Asia

SINGAPORE, Aug. 05, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that Precision Health Research, Singapore (PRECISE) has chosen the Revio HiFi sequencing system for its Long-Read Sequencing Flagship Project. This initiative aims to generate the largest long-read sequencing dataset in Southeast Asia, marking a significant... Read more

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies. New technology... Read more

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics. This approach could potentially be adapted for diagnosis of other... Read more

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral... Read more

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Danaher Launches Collaboration with Cincinnati Children’s Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development,... Read more

Bruker Announces Agreement to Acquire Chemspeed

Chemspeed Accelerates Bruker’s Laboratory Automation and Digitalization Drive BASEL, Switzerland–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, aSwiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research... Read more

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas LumiraDx’s technology integrates multiple Point of Care tests on a simple to use single instrument and brings more affordable and accessible testing to patients worldwide Under the terms of the agreement,... Read more